TABLE 1.

Best Overall Response and Objective Response Rates

	Nivolumab (n=410)	Everolimus (n=411)	Crossover to nivolumab (n=65)
Objective response rate, n (%) 95% CI	94 (22.9) 18.9–27.3	17 (4.1) 2.4–6.5	5 (7.7) 2.5–17.0
Odds ratio (95% CI)	6.86 (4.0–11.7)		–
Best overall response, n (%)
Complete response	4 (1.0)	2 (0.5)	1 (1.5)
Partial response	90 (22.0)	15 (3.6)	4 (6.2)
Stable disease	140 (34.1)	224 (54.5)	3 (4.6)
Progressive disease	142 (34.6)	106 (25.8)	49 (75.4)
Unable to determine	34 (8.3)	64 (15.6)	8 (12.3)
Ongoing response, n/N (%)	26/94 (27.6)	3/17 (17.6)	2/5 (40.0)

CI, confidence interval.